Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system.

Celia C, Ferrati S, Bansal S, van de Ven AL, Ruozi B, Zabre E, Hosali S, Paolino D, Sarpietro MG, Fine D, Fresta M, Ferrari M, Grattoni A.

Adv Healthc Mater. 2014 Feb;3(2):230-8. doi: 10.1002/adhm.201300188. Epub 2013 Jul 23.

2.

Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration.

Grattoni A, Shen H, Fine D, Ziemys A, Gill JS, Hudson L, Hosali S, Goodall R, Liu X, Ferrari M.

Pharm Res. 2011 Feb;28(2):292-300. doi: 10.1007/s11095-010-0195-6. Epub 2010 Jul 1.

PMID:
20593302
3.

Thermosensitive liposomal drug delivery systems: state of the art review.

Kneidl B, Peller M, Winter G, Lindner LH, Hossann M.

Int J Nanomedicine. 2014 Sep 16;9:4387-98. doi: 10.2147/IJN.S49297. eCollection 2014. Review.

4.

RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.

Wang F, Chen L, Zhang R, Chen Z, Zhu L.

J Control Release. 2014 Dec 28;196:222-33. doi: 10.1016/j.jconrel.2014.10.012. Epub 2014 Oct 22.

PMID:
25456829
5.

Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice.

Isacchi B, Bergonzi MC, Grazioso M, Righeschi C, Pietretti A, Severini C, Bilia AR.

Eur J Pharm Biopharm. 2012 Apr;80(3):528-34. doi: 10.1016/j.ejpb.2011.11.015. Epub 2011 Nov 28.

PMID:
22142592
6.

Leveraging nanochannels for universal, zero-order drug delivery in vivo.

Ferrati S, Fine D, You J, De Rosa E, Hudson L, Zabre E, Hosali S, Zhang L, Hickman C, Sunder Bansal S, Cordero-Reyes AM, Geninatti T, Sih J, Goodall R, Palapattu G, Kloc M, Ghobrial RM, Ferrari M, Grattoni A.

J Control Release. 2013 Dec 28;172(3):1011-9. doi: 10.1016/j.jconrel.2013.09.028. Epub 2013 Oct 3.

PMID:
24095805
7.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
9.
10.

Therapeutic efficacy of the combination of doxorubicin-loaded liposomes with inertial cavitation generated by confocal ultrasound in AT2 Dunning rat tumour model.

Mestas JL, Fowler RA, Evjen TJ, Somaglino L, Moussatov A, Ngo J, Chesnais S, Røgnvaldsson S, Fossheim SL, Nilssen EA, Lafon C.

J Drug Target. 2014 Sep;22(8):688-97. doi: 10.3109/1061186X.2014.906604. Epub 2014 Apr 14.

PMID:
24725154
11.

MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction.

Ren L, Chen S, Li H, Zhang Z, Zhong J, Liu M, Zhou X.

Acta Biomater. 2016 Apr 15;35:260-8. doi: 10.1016/j.actbio.2016.02.011. Epub 2016 Feb 9.

PMID:
26873364
12.

Liposomal drug delivery systems: from concept to clinical applications.

Allen TM, Cullis PR.

Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1. Review.

PMID:
23036225
13.

Lysolipid containing liposomes for transendothelial drug delivery.

Koklic T, Trancar J.

BMC Res Notes. 2012 Apr 10;5:179. doi: 10.1186/1756-0500-5-179.

14.

Challenges in development of targeted liposomal therapeutics.

Sawant RR, Torchilin VP.

AAPS J. 2012 Jun;14(2):303-15. doi: 10.1208/s12248-012-9330-0. Epub 2012 Mar 14. Review.

16.

Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.

Moosavian SA, Abnous K, Badiee A, Jaafari MR.

Colloids Surf B Biointerfaces. 2016 Mar 1;139:228-36. doi: 10.1016/j.colsurfb.2015.12.009. Epub 2015 Dec 15.

PMID:
26722819
17.

Liposomal drug formulations in the treatment of rheumatoid arthritis.

van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G.

Mol Pharm. 2011 Aug 1;8(4):1002-15. doi: 10.1021/mp2000742. Epub 2011 Jun 17. Review.

PMID:
21634436
18.

PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.

Shavi GV, Sreenivasa Reddy M, Raghavendra R, Nayak UY, Kumar AR, Deshpande PB, Udupa N, Behl G, Dave V, Kushwaha K.

J Liposome Res. 2016;26(1):28-46. doi: 10.3109/08982104.2015.1029493. Epub 2015 Apr 8.

PMID:
25853340
20.

Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.

Bandekar A, Zhu C, Gomez A, Menzenski MZ, Sempkowski M, Sofou S.

Mol Pharm. 2013 Jan 7;10(1):152-60. doi: 10.1021/mp3002717. Epub 2012 Dec 18.

PMID:
23134440

Supplemental Content

Support Center